GlassScriptPhysician profile
Kate Taylor
NPI 1700024932
$2,778.62
in general payments reported to CMS, 2019-2025
27 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.62 · 2022: $57.97 · 2023: $537 · 2024: $904 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $413.50 | 2022-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $216.09 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.01 | 2024-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $179.77 | 2021-2024 | Austedo Xr |
| Lilly USA, LLC | $156.35 | 2024-2025 | Mounjaro, Amyvid |
| Eisai INC. | $149.11 | 2025 | |
| Hologic Sales and Service, LLC | $133.80 | 2025 | Aptima |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.98 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $124.35 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $121.35 | 2025 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.75 | 2023 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $118.68 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $112.45 | 2024 | Tezspire |
| Krystal Biotech INC | $110.43 | 2024 | Vyjuvek |
| Corcept Therapeutics | $109.86 | 2024 | Korlym |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $65.15 | 2023 | Ingrezza, Ongentys |
| Mylan Specialty L.P. | $63.44 | 2022-2023 | Yupelri |
| Abbvie INC. | $54.95 | 2025 | |
| Biogen, INC. | $38.85 | 2021-2025 | Leqembi |
| Argenx US, INC. | $31.29 | 2023 | Vyvgart |
| Life Molecular Imaging LTD | $23.92 | 2025 | Neuraceq |
| Bayer Healthcare Pharmaceuticals INC. | $18.11 | 2024 | |
| Acadia Pharmaceuticals INC | $16.46 | 2022 | |
| C2n Diagnostics, LLC | $15.95 | 2025 | Precivityad2 |
| Alexion Pharmaceuticals, INC. | $15.87 | 2023 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $13.62 | 2024 | Crysvita |
| Exact Sciences Corporation | $13.53 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.